Characterization of Immune Semaphorin in Non Alcoholic Fatty Liver Disease and NASH
NCT ID: NCT02820285
Last Updated: 2017-10-05
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
148 participants
INTERVENTIONAL
2013-03-31
2016-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The role of immune semaphorin in regulating inflammation in the two compartments (liver and adipose tissue) could be a crucial step that could lead to more severe liver damage. Its dysregulation could explain NASH injuries. The goal is to identify a new mode of regulation of cellular homeostasis in the fatty liver disease. These factors may serve as diagnostic markers or future therapeutic targets.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
BASIC_SCIENCE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Morbid obese patients
Evaluation of the staging of fibrosis liver
The investigators will determine the severity of steatosis, inflammation and fibrosis by histological study of liver biopsies
Determine the expression level of semaphorin
The investigators will determine the expression level (gene and protein) of immune semaphorin and their (s) receptor (s) in the liver and subcutaneous and visceral adipose tissue by RT-PCR,
Determination of the composition of immunity cells
The investigators determine the composition of immunity cells by immunohistochemical and biochemical analyses (Western Blotting
)
Control patients
Evaluation of the staging of fibrosis liver
The investigators will determine the severity of steatosis, inflammation and fibrosis by histological study of liver biopsies
Determine the expression level of semaphorin
The investigators will determine the expression level (gene and protein) of immune semaphorin and their (s) receptor (s) in the liver and subcutaneous and visceral adipose tissue by RT-PCR,
Determination of the composition of immunity cells
The investigators determine the composition of immunity cells by immunohistochemical and biochemical analyses (Western Blotting
)
Patients with overweight, steatosis and steatohepatitis
Evaluation of the staging of fibrosis liver
The investigators will determine the severity of steatosis, inflammation and fibrosis by histological study of liver biopsies
Determine the expression level of semaphorin
The investigators will determine the expression level (gene and protein) of immune semaphorin and their (s) receptor (s) in the liver and subcutaneous and visceral adipose tissue by RT-PCR,
Determination of the composition of immunity cells
The investigators determine the composition of immunity cells by immunohistochemical and biochemical analyses (Western Blotting
)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Evaluation of the staging of fibrosis liver
The investigators will determine the severity of steatosis, inflammation and fibrosis by histological study of liver biopsies
Determine the expression level of semaphorin
The investigators will determine the expression level (gene and protein) of immune semaphorin and their (s) receptor (s) in the liver and subcutaneous and visceral adipose tissue by RT-PCR,
Determination of the composition of immunity cells
The investigators determine the composition of immunity cells by immunohistochemical and biochemical analyses (Western Blotting
)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients with body mass index justifying a surgery for obesity (BMI ≥ 40 kg / m2 or BMI ≥ 35 kg / m2 with comorbidities)
* Consumption of alcohol \<20 g / d
* Patients affiliated to a social security insurance
* Patients who signed the informed consent
Exclusion Criteria
* Toxic hepatitis
* Deficiency of alpha-1-antitrypsin
* Wilson's disease
* Liver Autoimmune disease (primary biliary cirrhosis, autoimmune hepatitis)
* Hepatitis B, C
* Drug-induced hepatitis
* Presence of HIV status
* Corticosteroids, amiodarone, valproic acid, tamoxifen, anti-inflammatory drugs, lipid lowering agents, testosterone agonists or beta-adrenergic antagonists, orlistat.
* Pregnant or breastfeeding women
* Incarcerated patients or patient under guardianship
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Centre Hospitalier Universitaire de Nice
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Albert TRAN, MDPhD
Role: PRINCIPAL_INVESTIGATOR
Centre Hospitalier Universitaire de Nice
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Service d'Hépato-Gastroentérologie - Hôpital de l'Archet
Nice, , France
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Sans A, Bailly L, Anty R, Sielezenef I, Gugenheim J, Tran A, Gual P, Iannelli A. Baseline Anthropometric and Metabolic Parameters Correlate with Weight Loss in Women 1-Year After Laparoscopic Roux-En-Y Gastric Bypass. Obes Surg. 2017 Nov;27(11):2940-2949. doi: 10.1007/s11695-017-2720-8.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
11-PP-10
Identifier Type: -
Identifier Source: org_study_id